Introduction:
Belgium-headquartered GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have formed a strategic collaboration. Under this agreement, GW Vitek will represent EuroscreenFast’s discovery and lead optimization capabilities in the Republic of Korea. This partnership will expand EuroscreenFast’s commercial reach into the Korean market by utilizing GW Vitek’s distribution network and market expertise. The aim is to provide cutting-edge GPCR cell-based assay services and a robust deorphanization offering to a broader range of clients.
- EuroscreenFast and GW Vitek have entered into a partnership to expand EuroscreenFast’s commercial reach in Korea.
- GW Vitek will represent EuroscreenFast’s discovery and lead optimization capabilities in the Republic of Korea.
- EuroscreenFast offers over 1,000 functional assays across more than 530 GPCR and other targets and has a strong deorphanization track record.
- The partnership will leverage GW Vitek’s distribution network and market expertise to provide cutting-edge GPCR cell-based assay services to a broader range of clients in Korea.
- GW Vitek’s CEO states that the partnership strengthens the company’s position as Korea’s provider of biotherapeutic research solutions for biologics and chemical therapeutics.
Conclusion:
Through their collaboration, EuroscreenFast and GW Vitek aim to bring EuroscreenFast’s advanced GPCR screening technologies to the Korean market. This partnership will allow EuroscreenFast to expand its presence in East Asia and provide its services to a wider range of clients in Korea. The partnership will also strengthen GW Vitek’s position as a provider of biotherapeutic research solutions in Korea. With EuroscreenFast’s expertise and GW Vitek’s market reach, both companies can contribute to advancements in GPCR science and drug discovery in the region.
